<DOC>
	<DOC>NCT00117117</DOC>
	<brief_summary>The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.</brief_summary>
	<brief_title>A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with nonmyeloid malignancy(ies) Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS) Unstable cardiac disease or anemia due to other causes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Chemotherapy induced anemia</keyword>
	<keyword>Amgen</keyword>
	<keyword>Aranesp®</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>